dc.contributor.author
Burock, Susen
dc.contributor.author
Herrmann, Pia
dc.contributor.author
Wendler, Ina
dc.contributor.author
Niederstrasser, Markus
dc.contributor.author
Wernecke, Klaus-Dieter
dc.contributor.author
Stein, Ulrike
dc.date.accessioned
2018-06-08T03:55:29Z
dc.date.available
2015-02-26T13:29:26.104Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/16219
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-20403
dc.description.abstract
METHODS: We provide for the first time a blood-based assay for transcript
quantification of the metastasis inducer MACC1 in a prospective study of
gastric cancer patient plasma. MACC1 is a strong prognostic biomarker for
tumor progression and metastasis in a variety of solid cancers. We conducted a
study to define the diagnostic and prognostic power of MACC1 transcripts using
76 plasma samples from gastric cancer patients, either newly diagnosed with
gastric cancer, newly diagnosed with metachronous metastasis of gastric
cancer, as well as follow-up patients. Findings were controlled by using
plasma samples from 54 tumor-free volunteers. Plasma was separated, RNA was
isolated, and levels of MACC1 as well as S100A4 transcripts were determined by
quantitative RT-PCR. RESULTS: Based on the levels of circulating MACC1
transcripts in plasma we significantly discriminated tumor-free volunteers and
gastric cancer patients (P < 0.001). Levels of circulating MACC1 transcripts
were increased in gastric cancer patients of each disease stage, compared to
tumor-free volunteers: patients with tumors without metastasis (P = 0.005),
with synchronous metastasis (P = 0.002), with metachronous metastasis (P =
0.005), and patients during follow-up (P = 0.021). Sensitivity was 0.68
(95%CI: 0.45-0.85) and specificity was 0.89 (95%CI: 0.77-0.95), respectively.
Importantly, gastric cancer patients with high circulating MACC1 transcript
levels in plasma demonstrated significantly shorter survival when compared
with patients demonstrating low MACC1 levels (P = 0.0015). Furthermore,
gastric cancer patients with high circulating transcript levels of MACC1 as
well as of S100A4 in plasma demonstrated significantly shorter survival when
compared with patients demonstrating low levels of both biomarkers or with
only one biomarker elevated (P = 0.001). CONCLUSION: Levels of circulating
MACC1 transcripts in plasma of gastric cancer patients are of diagnostic value
and are prognostic for patient survival in a prospective study.
en
dc.rights.uri
http://www.nature.com/cddis/about/open_access.html
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::616 Krankheiten
dc.title
Circulating metastasis associated in colon cancer 1 transcripts in gastric
cancer patient plasma as diagnostic and prognostic biomarker
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation
World J Gastroenterol. - 21 (2015), 1, S. 333-341
dcterms.bibliographicCitation.doi
10.3748/wjg.v21.i1.333
dcterms.bibliographicCitation.url
http://www.wjgnet.com/1007-9327/full/v21/i1/333.htm
refubium.affiliation
Charité - Universitätsmedizin Berlin
de
refubium.mycore.fudocsId
FUDOCS_document_000000021925
refubium.resourceType.isindependentpub
no
refubium.mycore.derivateId
FUDOCS_derivate_000000004587
dcterms.accessRights.openaire
open access